• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

心脏伴侣II型连续血流左心室辅助系统已知最长存活者——一个16年成功案例报告

Longest Known Survivor With HeartMate II Continuous-Flow Left Ventricular Assist System-A Case Report of the 16-Year Success Story.

作者信息

Chawa Yamane, Habib Mhd Baraa, Chapra Ammar, Elbdri Salah

机构信息

Internal Medicine Department Hamad Medical Corporation Doha Qatar.

Cardiology Department, Heart Hospital Hamad Medical Corporation Doha Qatar.

出版信息

Clin Case Rep. 2025 Jan 6;13(1):e9695. doi: 10.1002/ccr3.9695. eCollection 2025 Jan.

DOI:10.1002/ccr3.9695
PMID:39764263
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11702465/
Abstract

Left ventricular assist devices (LVADs) have been used as a bridge to transplantation in patients with advanced heart failure. In this case, LVAD therapy was used as a destination therapy for 16 years, representing the longest documented and continuously ongoing support with the original implanted device.

摘要

左心室辅助装置（LVADs）已被用作晚期心力衰竭患者移植的桥梁。在这种情况下，LVAD治疗作为目标治疗使用了16年，这是有记录以来使用原始植入装置持续支持时间最长的案例。

相似文献

1
Longest Known Survivor With HeartMate II Continuous-Flow Left Ventricular Assist System-A Case Report of the 16-Year Success Story.心脏伴侣II型连续血流左心室辅助系统已知最长存活者——一个16年成功案例报告
Clin Case Rep. 2025 Jan 6;13(1):e9695. doi: 10.1002/ccr3.9695. eCollection 2025 Jan.
2
Clinical and cost-effectiveness of left ventricular assist devices as destination therapy for advanced heart failure: systematic review and economic evaluation.左心室辅助装置作为晚期心力衰竭的终末期治疗的临床和成本效益：系统评价和经济评估。
Health Technol Assess. 2024 Aug;28(38):1-237. doi: 10.3310/MLFA4009.
3
HeartMate® II continuous-flow left ventricular assist system.HeartMate® II 连续血流左心室辅助系统。
Expert Rev Med Devices. 2011 Jan;8(1):11-21. doi: 10.1586/erd.10.77.
4
Improved survival and decreasing incidence of adverse events with the HeartMate II left ventricular assist device as bridge-to-transplant therapy.使用HeartMate II左心室辅助装置作为桥接至移植治疗可提高生存率并降低不良事件发生率。
Ann Thorac Surg. 2008 Oct;86(4):1227-34; discussion 1234-5. doi: 10.1016/j.athoracsur.2008.06.030.
5
Post-cardiac transplant survival after support with a continuous-flow left ventricular assist device: impact of duration of left ventricular assist device support and other variables.心脏移植后使用持续血流左心室辅助装置的生存情况：左心室辅助装置支持时间和其他变量的影响。
J Thorac Cardiovasc Surg. 2010 Jul;140(1):174-81. doi: 10.1016/j.jtcvs.2010.03.037. Epub 2010 May 5.
6
Left ventricular assist devices: an evidence-based analysis.左心室辅助装置：基于证据的分析
Ont Health Technol Assess Ser. 2004;4(3):1-69. Epub 2004 Mar 1.
7
Association of Clinical Outcomes With Left Ventricular Assist Device Use by Bridge to Transplant or Destination Therapy Intent: The Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 (MOMENTUM 3) Randomized Clinical Trial.临床结局与通过桥接移植或目的地治疗意向使用左心室辅助装置的关联：使用 HeartMate 3（MOMENTUM 3）机械循环支持治疗的多中心磁悬浮技术研究（MOMENTUM 3）随机临床试验。
JAMA Cardiol. 2020 Apr 1;5(4):411-419. doi: 10.1001/jamacardio.2019.5323.
8
Mechanical Circulatory Support for the Failing Heart: Continuous-Flow Left Ventricular Assist Devices.衰竭心脏的机械循环支持：连续流左心室辅助装置
Ochsner J. 2016 Fall;16(3):263-9.
9
Randomized trial of a left ventricular assist device as destination therapy versus guideline-directed medical therapy in patients with advanced heart failure. Rationale and design of the SWEdish evaluation of left Ventricular Assist Device (SweVAD) trial.随机试验：左心室辅助装置作为终末期心力衰竭患者的治疗目标与指南指导的药物治疗的比较。SWEdish evaluation of left Ventricular Assist Device（SweVAD）试验的原理和设计。
Eur J Heart Fail. 2020 Apr;22(4):739-750. doi: 10.1002/ejhf.1773. Epub 2020 Feb 26.
10
Nine Years of Continuous Flow LVAD (HeartMate 3): Survival and LVAD-Related Complications before and after Hospital Discharge.九年持续血流左心室辅助装置（HeartMate 3）：出院前后的生存率及与左心室辅助装置相关的并发症
J Cardiovasc Dev Dis. 2024 Sep 30;11(10):301. doi: 10.3390/jcdd11100301.

本文引用的文献

1
The Longest Living Patient Supported With Left Ventricular Assist Device (14 Years).最长生存的左心室辅助装置（14 年）支持患者。
ASAIO J. 2024 Oct 1;70(10):e147-e149. doi: 10.1097/MAT.0000000000002184. Epub 2024 Sep 26.
2
Exercise Performance and Quality of Life of Left Ventricular Assist Device Patients After Long-Term Outpatient Cardiac Rehabilitation.长期门诊心脏康复后左心室辅助装置患者的运动表现和生活质量。
J Cardiopulm Rehabil Prev. 2023 Sep 1;43(5):346-353. doi: 10.1097/HCR.0000000000000789. Epub 2023 Apr 5.
3
The Society of Thoracic Surgeons Intermacs 2022 Annual Report: Focus on the 2018 Heart Transplant Allocation System.胸外科医师协会Intermacs 2022年度报告：聚焦2018年心脏移植分配系统
Ann Thorac Surg. 2023 Feb;115(2):311-327. doi: 10.1016/j.athoracsur.2022.11.023. Epub 2022 Dec 1.
4
Twelfth Interagency Registry for Mechanically Assisted Circulatory Support Report: Readmissions After Left Ventricular Assist Device.第十二次机械循环辅助支持机构注册报告：左心室辅助装置后的再入院。
Ann Thorac Surg. 2022 Mar;113(3):722-737. doi: 10.1016/j.athoracsur.2021.12.011. Epub 2022 Jan 7.
5
Ten-year survival with HeartMate-II in situs viscerum inversus.HeartMate-II用于治疗内脏反位患者的十年生存率
Artif Organs. 2021 Jun;45(6):639-640. doi: 10.1111/aor.13882. Epub 2021 Jan 21.
6
Ten-Year Survival With a Continuous-Flow Left Ventricular Assist Device and Aortic Valve Closure.十年连续血流左心室辅助装置和主动脉瓣关闭的存活率。
Tex Heart Inst J. 2020 Aug 1;47(4):325-328. doi: 10.14503/THIJ-19-7193.
7
A Fully Magnetically Levitated Left Ventricular Assist Device - Final Report.全磁悬浮左心室辅助装置 - 最终报告。
N Engl J Med. 2019 Apr 25;380(17):1618-1627. doi: 10.1056/NEJMoa1900486. Epub 2019 Mar 17.
8
HeartMate II implantation technique that spares the sternum and ascending aorta.保留胸骨和升主动脉的HeartMate II植入技术。
J Artif Organs. 2018 Dec;21(4):458-461. doi: 10.1007/s10047-018-1049-y. Epub 2018 May 21.
9
Five-year results of patients supported by HeartMate II: outcomes and adverse events.HeartMate II 辅助患者的 5 年结果：结局和不良事件。
Eur J Cardiothorac Surg. 2018 Feb 1;53(2):422-427. doi: 10.1093/ejcts/ezx313.
10
Young woman with breast cancer and cardiotoxicity with severe heart failure treated with a HeartMate IITM for nearly 6 years before heart transplantation.患有乳腺癌且出现心脏毒性并伴有严重心力衰竭的年轻女性，在心脏移植前使用HeartMate II™进行了近6年的治疗。
ASAIO J. 2014 Nov-Dec;60(6):e3-4. doi: 10.1097/MAT.0000000000000138.